European Hematology Association - Daratumumab Maintenance Improves Progression-Free Survival After Autologous Stem Cell Transplantation in Multiple Myeloma Patients

Presenter:          Professor Phillipe Moreau Presenter:         ProfessorPhillipe Moreau Affiliation:           CHU de Nantes, Nantes,France Abstract:            #S180 DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE ± DARATUMUMAB AND ASCT:CASSIOPEIA PART2 RESULTS About the EHA Annual Congress: Every June, EHA organizes its Annual Congress in a major European city...

THE HAGUE, Netherlands, 12/06/2021 (informazione.news - comunicati stampa - scienza e tecnologia)

         Professor Phillipe Moreau

          CHU de Nantes, Nantes, France

              DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE ± DARATUMUMAB AND ASCT: CASSIOPEIA PART 2 RESULTS

About the EHA Annual Congress: Every June, EHA organizes its Annual Congress in a major European city. This year, due to the persisting COVID19 pandemic, EHA organizes a virtual Congress for the second time. The Congress is aimed at health professionals working in or interested in the field of hematology. The scientific program topics range from stem cell physiology and development to leukemia; lymphoma; diagnosis and treatment; red blood cells; white blood cells and platelet disorders; hemophilia and myeloma; thrombosis and bleeding disorders; as well as transfusion and stem cell transplantation.

Website: www.ehaweb.org